Alembic Pharma's JV Aleor Dermaceuticals gets USFDA nod for Metronidazole Gel

Aleor had previously received tentative approval for this ANDA.

Sep 06, 2021 02:09 IST India Infoline News Service

Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited has announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approvai from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1%.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Metrogel Gel, 1%, of Galderma Laboratories LP (Galderma). Metronidazole Gel USP, 1% is indicated for Indicated for the topical treatment of inflammatory lesions of rosacea. Aleor had previously received tentative approval for this ANDA.

Metronidazole Gel USP, 1% has an estimated market size of US$ 29 million for twelve months ending June 2021 according to IQVIA.

Alembic has a cumulative total of 149 ANDA approvals (132 final approvals and 17 tentative approvals) from USFDA.

At around 2:17 PM, Alembic Pharmaceuticals was trading at Rs782.15 apiece up by Rs7.65 or 0.99% on Sensex.

Related Story

Open Free Demat Account (Rs699)